← Back to Search

Non-invasive Brain Stimulation


Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of ADHD
8-16 years old
Must not have
Prior electroconvulsive therapy or vagus nerve stimulation
Diagnosis of Autism Spectrum Disorder.
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 5 (a decrease is an improvement)
Awards & highlights


This trial will test whether a treatment called repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD).

Who is the study for?
This trial is for children aged 8-16 with ADHD, an IQ over 80, and stable on current medication for at least 3 months. They must speak English to give consent. It's not suitable for those with autism, bipolar disorder, psychosis, mania or a history of certain brain treatments or metal implants.Check my eligibility
What is being tested?
The study is examining the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in reducing ADHD symptoms compared to standard treatment options.See study design
What are the potential side effects?
Possible side effects of rTMS include discomfort at the stimulation site, headache, lightheadedness, seizures (very rare), and temporary hearing changes due to the noise during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with ADHD.
I am between 8 and 16 years old.
I am between 8 and 16 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have had electroconvulsive therapy or vagus nerve stimulation before.
I have been diagnosed with Autism Spectrum Disorder.
I have been diagnosed with post-concussive syndrome before.
I have been diagnosed with mania, psychosis, or bipolar disorder.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 5 (a decrease is an improvement)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 5 (a decrease is an improvement) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Conners-3 Parent Rating Scale
Secondary outcome measures
GABA Concentration
Glutamate Concentration

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active rTMSExperimental Treatment1 Intervention
Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
Group II: Sham rTMSPlacebo Group1 Intervention
For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ADHD include stimulant medications like methylphenidate and amphetamines, which increase the levels of dopamine and norepinephrine in the brain, enhancing attention and reducing impulsivity and hyperactivity. Non-stimulant medications, such as atomoxetine, work by selectively inhibiting the reuptake of norepinephrine. Behavioral therapies focus on modifying behavior through reinforcement techniques. Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive treatment that modulates neural activity in the brain, potentially improving ADHD symptoms by targeting specific brain regions involved in attention and behavior regulation. Understanding these mechanisms is crucial for ADHD patients as it helps tailor treatments to individual needs, potentially improving outcomes and reducing symptoms.
Targeting repetitive transcranial magnetic stimulation in depression: do we really know what we are stimulating and how best to do it?Alleviation of ADHD symptoms by non-invasive right prefrontal stimulation is correlated with EEG activity.Transcranial magnetic stimulation in neurology: what we have learned from randomized controlled studies.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
800 Previous Clinical Trials
875,140 Total Patients Enrolled

Media Library

rTMS (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04532190 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Active rTMS, Sham rTMS
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT04532190 — N/A
rTMS (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04532190 — N/A
~13 spots leftby Dec 2025